CIK 0002036042 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Sionna Therapeutics, Inc.
Sign in to watch- Ticker
- SION
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-819-2020
- Business address
- 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $21,835,018
- in 1 filing
Net −$21,835,018. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Beer Caroline Stark Chief Business Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +139,340 | 139,340 | ||
| 2026-01-02 | Fitzpatrick Jennifer Chief Legal Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +103,140 | 103,140 | ||
| 2026-01-02 | McKee Charlotte Chief Medical Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +155,700 | 155,700 | ||
| 2026-01-02 | Ridloff Elena CFO | Grant or award · Non-Qualified Stock Option (right to buy) | +165,440 | 165,440 | ||
| 2026-01-02 | Cloonan Michael President & CEO | Grant or award · Non-Qualified Stock Option (right to buy) | +436,100 | 436,100 | ||
| 2025-12-24 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −33,356 | $44.55 | $1.5M | 3,561,655 |
| 2025-12-24 | Thompson Peter A. Director | Sale 10b5-1 | −33,356 | $44.55 | $1.5M | 3,561,655 |
| 2025-12-19 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −875 | $44.49 | $39K | 3,595,011 |
| 2025-12-19 | Thompson Peter A. Director | Sale 10b5-1 | −875 | $44.49 | $39K | 3,595,011 |
| 2025-12-18 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −100 | $44.49 | $4K | 3,595,886 |
| 2025-12-18 | Thompson Peter A. Director | Sale 10b5-1 | −100 | $44.49 | $4K | 3,595,886 |
| 2025-12-17 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −900 | $44.50 | $40K | 3,595,986 |
| 2025-12-17 | Thompson Peter A. Director | Sale 10b5-1 | −900 | $44.50 | $40K | 3,595,986 |
| 2025-12-05 | Fitzpatrick Jennifer Chief Legal Officer | Option exercise 10b5-1 | +10,250 | $6.11 | $63K | 10,250 |
| 2025-12-05 | Fitzpatrick Jennifer Chief Legal Officer | Sale 10b5-1 | −10,250 | $40.52 | $415K | 0 |
| 2025-12-05 | Fitzpatrick Jennifer Chief Legal Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −10,250 | 61,185 | ||
| 2025-11-26 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −1,600 | $44.49 | $71K | 3,596,886 |
| 2025-11-26 | Thompson Peter A. Director | Sale 10b5-1 | −1,600 | $44.49 | $71K | 3,596,886 |
| 2025-11-25 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −11,890 | $44.60 | $530K | 3,598,486 |
| 2025-11-25 | Thompson Peter A. Director | Sale 10b5-1 | −11,890 | $44.60 | $530K | 3,598,486 |
Page 4 of 15 · 284 trades